Taysha Gene Therapies Inc...

1.59
-0.28 (-14.97%)
At close: Feb 11, 2025, 3:59 PM
1.64
3.31%
After-hours Feb 11, 2025, 06:58 PM EST
undefined%
Bid 1.6
Market Cap 325.35M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.63
PE Ratio (ttm) 2.52
Forward PE n/a
Analyst Buy
Ask 1.65
Volume 2,908,288
Avg. Volume (20D) 4,048,120
Open 1.85
Previous Close 1.87
Day's Range 1.50 - 1.85
52-Week Range 1.19 - 4.32
Beta undefined

About TSHA

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of ...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 24, 2020
Employees 52
Stock Exchange NASDAQ
Ticker Symbol TSHA

Analyst Forecast

According to 8 analyst ratings, the average rating for TSHA stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 340.94% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago
+2.71%
Taysha Gene Therapies shares are trading higher. C... Unlock content with Pro Subscription
3 months ago
+46.63%
Taysha Gene Therapies shares are trading higher. Needham reiterated a Buy rating on the stock and Cantor Fitzgerald reiterated an Overweight rating.